Global Acute Myocardial Infarction Market - 2025-2033

The global acute myocardial infarction market reached US$ 1,790.79 million in 2024 and is expected to reach US$ 3,065.81 million by 2033, growing at a CAGR of 6.7 % during the forecast period of 2025-2033.

The global acute myocardial infarction market encompasses a wide range of medical solutions aimed at the diagnosis, treatment and management of heart attacks on a global scale. This market includes pharmaceutical interventions such as antiplatelet agents, thrombolytics and anticoagulants, which play a crucial role in preventing further clot formation and restoring blood flow to the heart.

Additionally, medical devices such as stents, catheters and defibrillators are essential in emergency and long-term cardiac care. The market also covers advanced diagnostic tools that enable early detection and risk assessment, improving patient survival rates and reducing complications. Beyond pharmaceuticals and medical devices, the acute myocardial infarction market also includes surgical interventions like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), which are critical in restoring blood supply to the heart.

Market Dynamics: Drivers & Restraints

Aging Population and Increasing Prevalence of Cardiovascular Conditions

The aging population and increasing prevalence of cardiovascular conditions are expected to drive the growth of the global acute myocardial infarction market over the forecast period. As people age, they are more prone to developing heart-related conditions such as hypertension, coronary artery disease, and heart failure, which significantly increase the risk of acute myocardial infarction.

As per National Library of Medicine data in September 2023, acute myocardial infarction (AMI) remains a major contributor to mortality in the developed world and a significant concern in the global AMI market. The disease affects approximately 3 million people worldwide, with over 1 million deaths occurring annually in the United States alone.

Around 70% of fatal AMI cases are linked to arterial occlusion caused by atherosclerotic plaque buildup, making atherosclerosis the primary underlying cause of heart attacks. Given its critical role in AMI, the market increasingly focuses on preventive strategies, risk factor management, and innovative treatment solutions to address atherosclerotic disease and reduce AMI-related mortality. All these factors demand the global acute myocardial infarction market.

The significant growth in the global AMI market is being driven by a combination of factors, including the high prevalence of the disease, advancements in treatment options, preventive healthcare efforts, and technological innovations. As research continues to enhance early detection, intervention, and post-AMI care, the market is poised for further expansion, creating new opportunities for industry players.

High Cost of AMI Treatment & Cardiac Procedures

The high cost of AMI treatment and cardiac procedures presents a significant restraint in the global acute myocardial infarction (AMI) market. Treatment for AMI often involves a combination of pharmaceutical therapies, medical devices, and surgical interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). This high cost can limit patient access to optimal care, particularly in low-income populations or in developing regions, where healthcare resources are more constrained. Furthermore, the long-term care and rehabilitation required after an AMI event can add to the financial burden on patients and healthcare systems.

According to the American Heart Association, Inc., research data in February 2024 stated that the economic burden of treatment varies significantly based on the intervention required. The cost of managing an AMI event without percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is the lowest, averaging $21,898.

However, the financial impact increases substantially with more advanced procedures, with AMI cases requiring PCI costing approximately $31,522, while those necessitating CABG rise to $71,788 more than three times the cost of AMI management without these interventions. These high treatment expenses present a significant restraint in the global AMI market, influencing healthcare accessibility, reimbursement policies, and overall cost-effectiveness considerations for cardiovascular care. Thus, the above factors could be limiting the global acute myocardial infarction market's potential growth.

Segment Analysis

The global acute myocardial infarction market is segmented based on treatment type, route of administration and region.

Treatment Type:

The antiplatelet agents segment in treatment type is expected to dominate the global acute myocardial infarction market with the highest market share

Acute myocardial infarction (AMI) is a critical cardiovascular condition that significantly contributes to global morbidity and mortality. In the global AMI market, antiplatelet therapies play a vital role in managing the condition by reducing the risk of major adverse cardiovascular events and recurrent myocardial infarction (MI). These treatments are essential for improving patient outcomes and are a key focus of ongoing advancements in cardiovascular care.

According to the Cureus research publication in March 2023, antiplatelet therapies such as abciximab, tirofiban, and eptifibatide are widely utilized in the treatment of ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

These agents are commonly administered alongside standard therapies, including aspirin, clopidogrel, prasugrel, and anticoagulants like heparin or bivalirudin. Typically, abciximab and tirofiban are given as an IV bolus 10 to 60 minutes before PCI, followed by continuous infusion. Additionally, research has indicated that tirofiban and abciximab demonstrate comparable effectiveness in AMI treatment. These findings continue to shape the evolving landscape of antiplatelet therapies in the global AMI market. These factors have solidified the segment's position in the global acute myocardial infarction market.

Geographical Analysis

North America is expected to hold a significant position in the global acute myocardial infarction market with the highest market share

North America has a high incidence of cardiovascular diseases, including AMI, due to factors such as unhealthy diets, sedentary lifestyles, smoking, and high rates of obesity and diabetes. These risk factors significantly increase the prevalence of AMI, which drives demand for treatment options, including pharmaceuticals, medical devices, and surgical interventions.

According to the Centers for Disease Control and Prevention (CDC) stats in October 2024, in North America, particularly in the United States, a heart attack occurs every 40 seconds, with approximately 805,000 people experiencing a heart attack annually. This high incidence significantly drives the demand for acute myocardial infarction (AMI) treatments and related healthcare services, making the region a key market for cardiovascular care and innovative solutions aimed at reducing heart attack-related morbidity and mortality.

For instance, in March 2025, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved TNKase (tenecteplase), a thrombolytic agent, for the treatment of acute myocardial infarction (AMI) in adults. This approval strengthens Genentech's presence in the global AMI market, highlighting its commitment to advancing cardiovascular care. With TNKase and Activase (alteplase), Genentech remains a key player in developing FDA-approved therapies for AMI, reinforcing its leadership in innovative treatments for thrombotic conditions. Thus, the above factors are consolidating the region's position as a dominant force in the global acute myocardial infarction market.

Competitive Landscape

The major global players in the acute myocardial infarction market include AGEPHA Pharma FZ-LLC, Genentech, Inc., Sanofi, Boehringer Ingelheim International GmbH. (Eli Lilly and Company), Bayer AG, Daiichi Sankyo Company, Limited, AstraZeneca, Pfizer Inc., Fresenius Kabi, Viatris Inc. (Idorsia) and among others.

Key Developments

• In February 2024, Global biotechnology leader CSL announced top-line results from the Phase 3 AEGIS-II trial, which assessed the efficacy and safety of CSL112 (apolipoprotein A-I [human]) in reducing major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The trial did not achieve its primary efficacy endpoint of MACE reduction at 90 days. Consequently, CSL has no immediate plans for a regulatory filing. However, the study found no significant safety or tolerability concerns associated with CSL112.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global acute myocardial infarction market report delivers a detailed analysis with 54 key tables, more than 51 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.